Role of Magnesium Sulphate on Delirium after cancer surgery- A Randomized Controlled trial
Not Applicable
- Conditions
- Health Condition 1: D099- Carcinoma in situ, unspecified
- Registration Number
- CTRI/2023/10/058995
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA I-III
duration of surgery- more than 2 hours
extubation at the end of surgery
Exclusion Criteria
oPatients with preoperative neurocognitive dysfunction
oPatients not consenting to the study
oPatients who will be sent intubated to ICU
oPatients who are allergic to any of the study drugs
oPatients with MoCA score less than 26
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie magnesium sulphate's effect on postoperative delirium in oncological surgeries?
How does magnesium sulphate compare to standard-of-care deliriants in cancer surgery recovery?
Are there specific biomarkers that predict response to magnesium sulphate in postoperative delirium prevention?
What are the potential adverse events associated with magnesium sulphate in cancer surgery patients and how are they managed?
What combination therapies or alternative compounds show promise in mitigating postoperative delirium alongside magnesium sulphate in oncological settings?